TGTX

TG TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$53.00

-1.8% vs current

Most likely

Base case

45%

Probability

Target price

$44.50

-17.5% vs current

B-

Bear case

25%

Probability

Target price

$31.50

-41.6% vs current

AI sentiment snapshot

Latest data as of 2026-06-07

AI commentary

The tone is constructive and company-source driven: the May 6 8-K confirmed the earnings release, the packet's stored earnings context points to strong BRIUMVI-led revenue growth and a raised outlook, and the June 3 8-K added positive Phase 1 subcutaneous ublituximab PK/PD and tolerability data. Forward visibility is better than for a typical filing-monitoring name, but the formulation opportunity is still early and the packet does not include a deep analyst revision tape. Social, options, short-interest, and employee-sentiment data are absent or insufficient, so they are not used to upgrade conviction.

RankAlpha Sentiment Codex - 2026-06-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-06eventQ1 2026 earnings release supported the commercial thesisMedium impact

The company confirmed its May 6 Q1 release via 8-K, and the packet's stored earnings context indicates BRIUMVI-led revenue growth, a revenue beat, and raised 2026 revenue guidance. That keeps the near-term commercialization story intact, but the hard numbers come from stored earnings context rather than the SEC filing excerpt alone. [#SEC-8K-2026-05-06] [#PR-EARNINGS-2026-06-05]

2026-06-03eventPositive Phase 1 subcutaneous ublituximab data added a new option value leverMedium impact

On June 3, the company filed an 8-K saying it had issued positive PK, PD, safety, and tolerability data from a Phase 1 clinical trial of a subcutaneous formulation of ublituximab in RMS. This is an early but meaningful de-risking step for a convenience-oriented formulation story. [#SEC-8K-2026-06-03]

2026-12-31catalystSubcutaneous BRIUMVI could support longer-duration adoption if development advancesHigh impact

If the subcutaneous formulation continues to validate and eventually clears regulatory review, it could improve convenience, infusion-center throughput, and adoption friction for BRIUMVI. The upside is real but still depends on later-stage data, filing strategy, and payer uptake. [#SEC-8K-2026-06-03]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-07 • Updated nightlySource: Internal modelMethodology